|AMEX: CRMD||Healthcare / Biotechnology / USA|
|3.41||+0.1200||+3.65%||Vol 156.37K||1Y Perf -47.28%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||15.00||Analyst Rating||Moderate Buy 2.00|
|Potential %||339.88||Finscreener Ranking||★★★★+ 56.39|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★★★+ 54.47|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★★★ 51.73|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||14.22||Earnings Rating||Strong Buy|
|Market Cap||140.77M||Earnings Date||30th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||30th Mar 2023|
|Estimated EPS Next Report||-0.19|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||187.94K|
|Avg. Monthly Volume||209.88K|
|Avg. Quarterly Volume||230.23K|
CorMedix Inc. (AMEX: CRMD) stock closed at 3.41 per share at the end of the most recent trading day (a 3.65% change compared to the prior day closing price) with a volume of 156.37K shares and market capitalization of 140.77M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 30 people. CorMedix Inc. CEO is Khoso Baluch.
The one-year performance of CorMedix Inc. stock is -47.28%, while year-to-date (YTD) performance is -19.19%. CRMD stock has a five-year performance of 224.76%. Its 52-week range is between 2.645 and 8.025, which gives CRMD stock a 52-week price range ratio of 14.22%
CorMedix Inc. currently has a PE ratio of -6.10, a price-to-book (PB) ratio of 3.38, a price-to-sale (PS) ratio of 5 133.39, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.50%, a ROC of -46.15% and a ROE of -50.90%. The company’s profit margin is -%, its EBITDA margin is -32 316.10%, and its revenue ttm is $35.71 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from CorMedix Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. CorMedix Inc.’s next earnings report date is 30th Mar 2023.
The consensus rating of Wall Street analysts for CorMedix Inc. is Moderate Buy (2), with a target price of $15, which is +339.88% compared to the current price. The earnings rating for CorMedix Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CorMedix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CorMedix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 29.34, ATR14 : 0.23, CCI20 : -100.08, Chaikin Money Flow : -0.37, MACD : -0.23, Money Flow Index : 18.21, ROC : -13.23, RSI : 38.55, STOCH (14,3) : 26.25, STOCH RSI : 0.98, UO : 39.32, Williams %R : -73.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CorMedix Inc. in the last 12-months were: Joseph Todisco (Buy at a value of $128 624), Myron Kaplan (Buy at a value of $18 900)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Strong Buy||Strong Buy|
Cormedix Inc is a biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution or the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology. The Neutrolin product is designed to target unmet medical need.
CEO: Khoso Baluch
Telephone: +1 908 517-9500
Address: 400 Connell Drive, Berkeley Heights 07922, NJ, US
Number of employees: 30
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.